Citadel Advisors
AEON icon

Citadel Advisors’s AEON Biopharma AEON Stock Holding History

Citadel Advisors’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,642
Closed -$12.8K – 12878
2025
Q4 		$12.8K Buy
+11,642
New +$10.9K ﹤0.01% 12413
2023
Q4 		– Sell
-147
Closed -$59.4K – 14181
2023
Q3 		$59.4K Buy
+147
New +$67.3K ﹤0.01% 11551
2023
Q1 		– Sell
-2,617
Closed -$1.89M – 14637
2022
Q4 		$1.89M Sell
2,617
-5,752
-69% -$4.12M ﹤0.01% 5588
2022
Q3 		$5.93M Buy
8,369
+23
+0.3% +$16.3K ﹤0.01% 3585
2022
Q2 		$5.89M Sell
8,346
-6,927
-45% -$4.89M ﹤0.01% 3507
2022
Q1 		$10.8M Sell
15,273
-18
-0.1% -$12.6K ﹤0.01% 2837
2021
Q4 		$10.7M Buy
15,291
+28
+0.2% +$19.7K ﹤0.01% 2963
2021
Q3 		$10.7M Buy
15,263
+6,958
+84% +$4.86M ﹤0.01% 2961
2021
Q2 		$5.76M Buy
+8,305
New +$5.81M ﹤0.01% 4133

Other funds holding AEON

DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's AEON Position: Q1 2026 in Review

Citadel Advisors sold out of AEON Biopharma (AEON) in Q1 2026, closing a stake of 11,642 shares — an estimated $12.8K sold.

Citadel Advisors first reported a position in AEON in Q2 2021 and held it in 9 quarters. The position peaked at $10.8M in Q1 2022. 24 funds tracked by Wall St. Rank hold AEON as of Q1 2026.

  • Citadel Advisors reported no remaining AEON Biopharma position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 11,642 AEON Biopharma shares in Q1 2026, an estimated $12.8K.
  • Citadel Advisors first reported a position in AEON Biopharma in Q2 2021 and held it in 9 quarters.
  • Citadel Advisors's AEON Biopharma position peaked at $10.8M in Q1 2022.
  • 24 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.